New West Australian Study Investigates Alternative Endometriosis Treatment

A West Australian study is investigating an alternative pain treatment for endometriosis, a condition affecting one in seven women with debilitating pain caused by tissue growth outside the uterus.

The Microvascular Modulation in Endometriosis (MMEND) study, conducted by the Curtin Medical Research Institute and Perron Institute, will explore whether extracts from aged garlic bulbs and specific amino acids can reduce inflammation and minimize pain in patients.

Some participants in the MMEND study will receive a single component, while others will receive a combination to determine treatment efficacy.

Scientific Basis and Origin

Professor John Mamo, head of neurovascular and metabolic diseases at Perron Institute and Curtin University, stated that the treatment's potential effectiveness stems from evidence suggesting endometriosis is an inflammatory condition that may impair capillary blood flow.

The trial's origin traces back to a migraine study where female participants anecdotally reported reduced endometrial pain.

Potential Advantages of the New Treatment

Clinical trial co-ordinator Emily Redwood highlighted that a successful treatment could offer a more cost-effective option with fewer side effects compared to existing medications, which often have limitations for long-term use.

Participant Recruitment for the MMEND Study

The study is currently recruiting participants for the 56-week trial.

Eligible individuals must have a confirmed endometriosis diagnosis, reside in Perth, be aged 18-45, and not be pregnant, breastfeeding, or planning a pregnancy within the next 56 weeks.